



PATENT APPLICATION

1632
#5
KP
5-28-02
attachment

In re application of

Per Sonne HOLM, et al.

Appln. No.: 10/029,574

Group Art Unit: 1632

Filed: December 20, 2001

For: AGENTS FOR TREATING MALIGNANT DISEASES USING PROTEIN YB-1

Attorney Docket No.: 3961.002

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 and §1.98

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RECEIVED
APR 19 2002
TECH CENTER 1600/2900

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the following documents for the above-identified application. Copies of the documents set forth below and listed on the attached Form PTO-1449, and copies of the search reports, are provided herewith.

1. World Patent No. WO 94/18992
2. U.S. Patent No. 5,856,181
3. Kirn, D. (reprint), et al.; Adenovirus E1A mutants that selectively replicate in and cause enhanced destruction of cancer cells in vitro and in nude mouse-human tumor xenografts; Cancer Gene Therapy, (Nov.-Dec. 1998), Vol. 5, No. 6, Supp.[s], pp. 079-079

U.S. PATENT APPLICATION
SERIAL NO.: 10/029,574
INFORMATION DISCLOSURE STATEMENT

ATTY DOCK: 3961.002

4. Bargou, Ralf C., et al.; Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression; Nature Medicine, Vol. 3, No. 4, 1997, pp. 4470450, XP002160622, ISSN: 1078-8956
5. Heise, et al.; ONYX-015, an E+B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemo-therapeutic agents; Nature Medicine, Vol. 3, No. 6, June 1, 1997, pp. 639-645, XP0020953838, ISSN: 1078-8956

The present Information Disclosure Statement is being filed after three months from the application's filing date but before the mailing date of the first Office Action on the merits, therefore no Certification Under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedated or otherwise remove any listed document as a competent reference against the claims of the present application.

U.S. PATENT APPLICATION
SERIAL NO.: 10/029,574
INFORMATION DISCLOSURE STATEMENT

ATTY DOCK: 3961.002

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,



Stephan A. Pendorf
Reg. No. 32, 665


Pendorf & Cutliff
P.O. Box 20445
Tampa, Florida 33622-0445
(813)886-6085

Dated: April 9, 2002

CERTIFICATE OF MAILING AND AUTHORIZATION TO CHARGE

I hereby certify that the foregoing INFORMATION DISCLOSURE STATEMENT Form PTO-1449, including five documents, for U.S. Application No. 10/029,574 filed December 20, 2001, were deposited in first class U.S. mail, postage prepaid, Washington, D.C. 20231, on April 9, 2002.


The Commissioner is hereby authorized to charge any additional fees which may be required at any time during the prosecution of this application without specific authorization, or credit any overpayment, to Deposit Account No. 16-0877.



Stephan A. Pendorf

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 3961.002	SERIAL NO. 10/029,574
	APPLICANT(S) Per Sonne HOLM, et al.	
	FILING DATE 12/20/01	GROUP 1632

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,856,181	01/05/99	McCormick	C12N	5/10		



RECEIVED
 APR 19 2002
 TECH CENTER 1600/2500

FOREIGN PATENT DOCUMENTS								
*	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 94/18992	09/01/94	World	A61K	35/76	✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
*	EXAMINER INITIAL		Kirn, D. (reprint), et al.; Adenovirus E1A mutants that selectively replicate in and cause enhanced destruction of cancel cells in vitro and in nude mouse-human tumor xenografts; Cancer Gene Therapy, (Nov.-Dec. 1998), Vol. 5, No. 6, Supp. [s], pp. 079-079
			Bargou, Ralf C., et al.; Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression; Nature Medicine, Vol. 3, No. 4, 1997, pp. 4470450, XP002160622, ISSN: 1078-8956

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

